Friday, 16 October 2026European Markets

BORGESTAD Stock Was Up By 15% On Thursday

Loading stream...

(VIANEWS) - The Market ended the session with BORGESTAD (BOR.OL) rising 15% to kr0.35 on Thursday, following the last session's downward trend. Oslo Børs Benchmark Index_GI slid 0.21% to kr1,304.40, after two sequential sessions in a row of gains, on what was a somewhat down trend exchanging session today.

BORGESTAD's last close was kr0.30, 85.15% under its 52-week high of kr2.02.

About BORGESTAD

Borgestad ASA develops, manufactures, distributes, and installs refractory products in Norway. The company also develops and manages real estate properties. Its properties include Agora Bytom, a shopping center with a gross area of 52,000 square meters and a rental area of approximately 30,000 square meters, as well as a parking garage with 820 parking lots in Poland. Borgestad ASA was founded in 1904 and is headquartered in Skien, Norway.

Earnings Per Share

As for profitability, BORGESTAD has a trailing twelve months EPS of kr-0.3.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -15.11%.

Volume

Today's last reported volume for BORGESTAD is 10653300 which is 290.41% above its average volume of 2728690.

Revenue Growth

Year-on-year quarterly revenue growth grew by 31.8%, now sitting on 1.02B for the twelve trailing months.

More news about BORGESTAD (BOR.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com